These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2416059)

  • 1. Determinants of von Willebrand factor activity elicited by ristocetin and botrocetin: studies on a human von Willebrand factor-binding antibody.
    Brinkhous KM; Fricke WA; Read MS
    Semin Thromb Hemost; 1985 Oct; 11(4):337-41. PubMed ID: 2416059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
    Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
    Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of botrocetin with normal or variant von Willebrand factor (types IIA and IIB) and its inhibition by monoclonal antibodies that block receptor binding.
    Fujimura Y; Miyata S; Nishida S; Miura S; Kaneda M; Yoshioka A; Fukui H; Katayama M; Tuddenham EG; Usami Y
    Thromb Haemost; 1992 Oct; 68(4):464-9. PubMed ID: 1280375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venom coagglutinin for detection of von Willebrand factor activity in animal plasmas.
    Read MS; Potter JY; Brinkhous KM
    J Lab Clin Med; 1983 Jan; 101(1):74-82. PubMed ID: 6600265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin.
    Miura S; Nishida S; Makita K; Sakurai Y; Shimoyama T; Sugimoto M; Yoshioka A; Ishii K; Kito M; Kobayashi T; Fujimura Y
    Anal Biochem; 1996 May; 236(2):215-20. PubMed ID: 8660497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L; Jenkins PV; Gaucher C; Meriane E; Collins PW; Pasi KJ; Mazurier C
    Thromb Haemost; 2000 Aug; 84(2):188-94. PubMed ID: 10959688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of small molecular forms of human factor VIII/von Willebrand factor with botrocetin and anti-factor VIII-coated latex particles.
    Furlan M; Perret BA; Beck EA
    Thromb Haemost; 1985 Aug; 54(2):463-5. PubMed ID: 3936216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib.
    Girma JP; Fressinaud E; Christophe O; Rouault C; Obert B; Takahashi Y; Meyer D
    Thromb Haemost; 1992 Dec; 68(6):707-13. PubMed ID: 1287886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex.
    Andrews RK; Booth WJ; Gorman JJ; Castaldi PA; Berndt MC
    Biochemistry; 1989 Oct; 28(21):8317-26. PubMed ID: 2557900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model.
    Sanders WE; Read MS; Reddick RL; Garris JB; Brinkhous KM
    Lab Invest; 1988 Oct; 59(4):443-52. PubMed ID: 3262788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand factor without the A2 domain is resistant to proteolysis.
    Lankhof H; Damas C; Schiphorst ME; Ijsseldijk MJ; Bracke M; Furlan M; Tsai HM; de Groot PG; Sixma JJ; Vink T
    Thromb Haemost; 1997 May; 77(5):1008-13. PubMed ID: 9184419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin.
    Berndt MC; Ward CM; Booth WJ; Castaldi PA; Mazurov AV; Andrews RK
    Biochemistry; 1992 Nov; 31(45):11144-51. PubMed ID: 1359905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.